GeoVax Announces Multiple Patent Issuances and Allowances

Intellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced multiple actions by global patent offices strengthening the Company's intellectual property assets. The Japanese Patent Office issued a Decision of Grant notifying GeoVax of the a ...